NCT04820439View on ClinicalTrials.gov

Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

March 13, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)

A single intravenous infusion of HS627 420mg

DRUG

Perjeta ®

A single intravenous infusion of Perjeta ®420mg

Trial Locations (1)

266003

Phase I Clinical Research Center, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER

NCT04820439 - Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection | Biotech Hunter | Biotech Hunter